- Home
- ACLX
ACLX
Arcellx Inc.
as 02-21-2025 4:00pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Arcellx Inc. ACLX prepares to release earnings report on 26 Feb 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.6B | IPO Year: | 2022 |
| Target Price: | $107.67 | AVG Volume (30 days): | 532.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.88 - $107.37 | Next Earning Date: | 02-26-2025 |
| Revenue: | $155,818,000 | Revenue Growth: | 230.33% |
| Revenue Growth (this year): | 12.58% | Revenue Growth (next year): | -2.75% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | Feb 4 '25 | Sell | $64.57 | 1,500 | $96,855.00 | 0 | |
| Patel Kavita | ACLX | Director | Jan 14 '25 | Sell | $66.30 | 1,500 | $98,801.21 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Jan 7 '25 | Sell | $75.43 | 18,009 | $1,355,024.32 | 13,579 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 7 '25 | Sell | $74.61 | 7,783 | $581,315.58 | 25,085 | |
| Elghandour Rami | ACLX | SEE REMARKS | Jan 7 '25 | Sell | $74.61 | 30,311 | $2,263,941.87 | 117,275 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Jan 2 '25 | Sell | $78.36 | 21,847 | $1,712,352.66 | 13,579 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Jan 2 '25 | Sell | $78.36 | 18,674 | $1,463,818.53 | 25,085 | |
| Elghandour Rami | ACLX | SEE REMARKS | Jan 2 '25 | Sell | $78.36 | 58,856 | $4,613,094.36 | 117,275 | |
| Patel Kavita | ACLX | Director | Dec 24 '24 | Sell | $77.27 | 1,500 | $115,450.54 | 0 | |
| Patel Kavita | ACLX | Director | Dec 3 '24 | Sell | $92.02 | 1,500 | $137,817.72 | 0 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Is Arcellx (ACLX) Poised to Capture Significant Market Share?
Zacks
a month ago
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 01/13/2025
MT Newswires
a month ago
Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing
MT Newswires
a month ago
Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing
Zacks
a month ago
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?
MT Newswires
a month ago
Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing
Investor's Business Daily
2 months ago
Arcellx Stock Earns 82 Relative Strength Rating
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.